Digs Raises $25.3M Series A for AI Homebuilding Platform

Keenable.ai

Keenable.ai is building the next Google for AI Agents — the essential layer that connects AI agents to world knowledge and in future to each other, powering the $1T agentic economy

Alice (Formerly ActiveFence)

Alice is a trust, safety, and security company built for the AI era. We safeguard the communicative technologies people use to create, collaborate, and interact - whether with each other or with machines. In a world where AI has fundamentally changed the nature of risk, Alice provides end-to-end coverage across the entire AI lifecycle. We support frontier model labs, enterprises, and UGC platforms with a comprehensive suite of solutions: from model hardening evaluations and pre-deployment red-teaming to runtime guardrails and ongoing drift detection. Alice represents the next chapter of our growth and the natural evolution of ActiveFence, our industry-leading solution for UGC safety, as we expand our mission to secure the future of AI. Advance unafraid: alice.io

Emerald AI

Emerald AI transforms energy-intensive data centers into AI-powered grid allies. The Emerald AI Conductor platform enables AI data centers to flexibly adjust their power consumption from the electricity grid on demand, orchestrating the computing loads of inference, training, and fine-tuning AI models across a network of data centers to bolster the power grid’s reliability while meeting strict compute performance standards. Flexibility could unlock up to 100 GW, or more than a decade of U.S. AI data center growth and trillions in AI investment, without enormous investments in electric grids or power plants—advancing innovation and competitiveness, ensuring power affordability for communities across the country, and bolstering the reliability of the electric power system.

Airway Therapeutics

Created in 2011 as a spin-out of Cincinnati Children's Hospital Medical Center (CCHMC), Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is in advanced preclinical phase of developing AT-100 (rhSP-D), a product targeting bronchopulmonary dysplasia (BPD) in newborns.